Mitochondrial Dysfunction and Immune Cell Metabolism in Sepsis

Dae Won Park; Jaroslaw W Zmijewski

doi:10.3947/ic.2017.49.1.10

Journal List > Infect Chemother > v.49(1) > 1035448

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Zmijewski: Mitochondrial Dysfunction and Immune Cell Metabolism in Sepsis

Review Article

Infection & Chemotherapy 2017; 49(1): 10-21.

Published online: 23 March 2017

DOI: https://doi.org/10.3947/ic.2017.49.1.10

Mitochondrial Dysfunction and Immune Cell Metabolism in Sepsis

Dae Won Park¹

, Jaroslaw W Zmijewski²

¹Division of Infectious Diseases, Korea University Ansan Hospital, Ansan, Korea.

²Division of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Corresponding Author: Jaroslaw W Zmijewski, PhD. Division of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham, School of Medicine, 901 19th St. South, BMRII 304. Birmingham, AL35294, USA. Phone: +1-205-934-7437, zmijewsk@uab.edu

Received 21 March 2017

(open-access, http://creativecommons.org/licenses/by-nc/3.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Sepsis is a life threatening condition mediated by systemic infection, but also triggered by hemorrhage and trauma. These are significant causes of organ injury implicated in morbidity and mortality, as well as post-sepsis complications associated with dysfunction of innate and adaptive immunity. The role of cellular bioenergetics and loss of metabolic plasticity of immune cells is increasingly emerging in the pathogenesis of sepsis. This review describes mitochondrial biology and metabolic alterations of immune cells due to sepsis, as well as indicates plausible therapeutic opportunities.

Keywords: Sepsis, Multi-organ failure, Mitochondria, Immune cell, Metabolism

Introduction

Sepsis, the leading cause of death among critically ill patients, is a syndrome characterized by initial exaggerated systemic inflammatory response to infection or trauma followed by relatively prompt immune dysfunction. In acutely ill patients, a robust inflammatory response to severe sepsis is typically linked with multiple organ dysfunction syndrome (MODS), whereas septic shock is in addition associated with hypotension that does not respond to fluid resuscitation and vasopressors [1 2]. The mortality rates are from 25 to 30% for severe sepsis and up to 30-40% in shock [3 4]. Importantly, while early diagnosis and antibiotic therapy improved survival, post-sepsis complications have devastating impact. In particular, cognitive impairment, physical disabilities and frailty link to susceptibility to injury and infections, as well as poor recovery are associated with high mortality among sepsis survivors [5].

Organ dysfunction from sepsis is traditionally attributable to the effects of inflammatory mediators and tissue hypoxia and cell damage [6 7 8]. Organ injury is especially detrimental in lung and kidney, where regenerative capacity is limited. Surprisingly, several studies have found a substantial discordance between histological analysis and the degree of organ failure in patients who died from sepsis [9 10 11]. Little or no apoptosis or necrosis was found and in many cases tissue oxygen delivery was preserved [9]. Notably, most clinical trials revealed little or no effects of the anti-inflammatory therapy [12 13]. Low efficacy of anti-inflammatory drugs raises many questions about duration of tested therapies, pre-existing conditions and apparently multifactorial causes of sepsis. However, it is suggested that despite of oxygen bioavailability sepsis has a profound impact on cellular metabolism along with impairment of mitochondrial function [14 15]. In particular, a reduced cellular respiration, also termed “cell hibernation” or “cytopathic hypoxia”, may be initially linked to cells survival, but afterward can trigger to multi-organ failure in sepsis [16 17]. The concept was developed by early studies that found abnormal swollen mitochondria in animal model of sepsis [18]. Subsequently, it has become apparent that sepsis is characterized by a reduced function of the mitochondrial respiratory chain and accompanied by free radical generation and bioenergetic reprograming toward glycolytic metabolism [19 20].

Sepsis has a tremendous impact on the immune system by affecting leukocytes pro-inflammatory activity, microbial eradication, viability and proliferation [21 22]. In the initial phase of infection or trauma, immune response encounters hyperinflammation. This event is associated by excessive accumulation of inflammatory cytokines and damage associated molecular pattern proteins (DAMPs) in tissue fluids and plasma [23 24]. The cytokine storm is also described as systemic inflammatory response syndrome (SIRS), that characterized an excessive release of inflammatory cytokines, including interleukin (IL) 1 and 17 and tumor necrosis factor alpha (TNF-α) [25]. However, initial leukocyte activation is leading to immune dysfunction and development of immunosuppression [26]. Critically ill patients often progress to immunosuppression within a few hours of sepsis diagnosis followed by increased susceptibility to lung infection persisting for several days or weeks. In addition to high risk of nosocomial infections, septic patients developing chronic critical illness for greater than 14 days progress to persistent inflammation, immunosuppression and catabolism syndrome (PICS). These conditions are associated by following ~20-40% mortality rate by the 2-year mark [27 28]. It is important to note that over 2.5 million survivors of severe sepsis, septic shock, and PICS are at risk of lung infection and death [28].

Recent advances in clinical and experimental sepsis provided a wide range of discoveries related to immunometabolism and bioenergetics. However, despite economic and social burden of sepsis, therapeutic interventions are limited, mostly to early administration of antibiotics and fluids resuscitation. An effective treatment for critically ill patients or to improve quality of life among sepsis survivors is crucially needed. In this review, we highlight metabolic alterations in immune and organ tissue homeostasis, and indicate emerging therapeutic opportunities.

Mitochondrial function and alignment with glucose oxidative metabolism

Mitochondrial bioenergetics consist oxidative phosphorylation (OxPhos) integrated with the glycolytic pathway of the Krebs cycle (Fig. 1). Glucose enters the cellular milieu through the glucose transporter 1 (Glut1) followed by conversion to pyruvate that is mediated by series of enzymatic steps, including glucose phosphorylation to glucose-6-phosphate (G-6-P) followed by conversion to pyruvate, reducing NAD⁺ to NADH and generating two ATP molecules. Following its transportation into the mitochondria through converted into acetyl-CoA, pyruvate is further oxidized to CO₂ via the Krebs cycle to generate NADH that is oxidized via the OxPhos. In particular, mitochondrial electron transfer chain (ETC) complexes are essential for generation of mitochondrial membrane potential and proton gradient that is further utilized for production of ATP at the complex V (ATP synthase). In addition to the breakdown of glucose via glycolysis, cells have the ability to metabolize other substrates, such as lipids and glutamine, which feed into the Krebs cycle and drive OxPhos. Fatty acid β-oxidation and glutaminolysis replenish the Krebs cycle intermediates acetyl-CoA and α-ketoglutarate, respectively, thereby fueling oxidative phosphorylation. Of note, during inflammation and/or reduced oxygen, ATP production is derived by breakdown of glucose due to glycolysis and pyruvate being routed toward lactate instead acetyl-CoA. In sepsis, this situation is associated with increased amounts of tissue localized and in systemic lactate, though impaired lactate clearance is also a contributing factor [29 30].

Figure 1

Integration of metabolic pathways

Glucose is metabolized to pyruvate through the glycolysis. Pyruvate (and fatty acids) enters the mitochondria where they are converted to acetyl-CoA. This enters the Krebs cycle that donates electrons to electron transport chain. Through OxPhos, electrons are sequentially transferred to generate a H⁺ gradient across the inner mitochondrial membrane, which drives the synthesis ATP. In addition to the glycolysis, cells have the ability to metabolize alternative substrates, such as lipids and glutamine. FAO and glutaminolysis replenish the Krebs cycle intermediates acetyl-CoA and α-ketoglutarate, respectively, thereby fueling OxPhos. PPP generates riboses for nucleotides synthesis.

PPP, pentose phosphate pathway; OxPhos, oxidative phosphorylation; FAO, fatty acid β-oxidation; ADP, adenosine diphosphate; ATP, adenosine triphosphate; ETC, electron transport chain.

Mitochondrial dysfunction correlates with sepsis-related multi-organ failure

Along with bioenergetics, mitochondria are involved in several crucial functions that include program cell death pathway, calcium flux and redox signaling [31 32 33 34]. The exact reason for mitochondrial dysfunction during sepsis is not well understood. However, inflammatory molecules such as nitric oxide (NO), carbon monoxide, and reactive oxygen/nitrogen species directly impair several components of the mitochondrial ETC complexes and mitochondrial respiration [16 35 36]. Additionally, lower metabolic rates in sepsis have been associated with decreased the amounts of mitochondrial DNA and expression of major components of ETC complexes [37]. This is significant issue because mitochondrial DNA code nearly eighty percent of mitochondrial protein. Besides decreased amounts of major components in mitochondrial respiratory chain complexes and ATP synthase, recent studies have shown diminished pyruvate dehydrogenase expression in sepsis and ARDS [38 39 40]. It is important to note that pre-existing factors contribute to the severity of sepsis, including cigarette smoking, environmental exposure to toxins, metabolic syndrome of diabetes and obesity and aging [41 42 43].

Clinical analysis of sepsis by Dr. Mervyn Singer laboratory has shown that the extent of mitochondrial impairment in lungs was correlated with mortality rate. In particular, sepsis-associated mortality is significant in patients that develop acute respiratory distress syndrome (ARDS) [44 45]. Patients who died from severe sepsis had decreased muscle ATP content while higher levels of ATP were seen in survivors [45]. Organ dysfunction and clinical illness were accompanied by decreases in metabolic rate and mitochondrial mass [37]. However, recovery of metabolic activity and organ function is possible, and were strongly regulated by expression of markers of mitochondrial biogenesis such as PRARgamma-coactivator-1a (PGC-1a), nuclear respiratory factors 1 and 2 (NRF-1 and -2), and via repression of the biogenesis suppressor nuclear receptor interacting protein-140 (RIP140) [37 46 47 48]. Moreover, most recent pre-clinical studies, and our results, indicated that not only preservation, but also mitochondrial biogenesis is an essential step in reestablishing immune or tissue organ homeostasis during recovery from sepsis [49 50 51].

Metabolic control of immune cell homeostasis and pro-inflammatory activation

Severe infections, trauma and hemorrhage are initially associated with hyperinflammatory state, which frequently leads to immunoparalysis. This situation is implicated in nosocomial infections (high risk of hospital-related infections), and community acquired pneumonia [26 52]. Recently, it has become apparent that these events are correlated with specific metabolic and bioenergetic alterations in immune cells [53 54]. Many immune cells lose their bioenergetic plasticity due to glycolytic and anabolic metabolism. Leukocytes from patients with severe sepsis show deficient cellular metabolism that were associated with a defective response to secondary stimulation. Notably, recent studies suggest that both glycolysis and OxPhos are impaired in monocytes of post-septic immunosuppressed patients [55 56].

1. Neutrophils

Neutrophils are most abundant leukocytes in circulation. Along with macrophages, they are a first line of innate immune response during microbial infections in traumatic injury [57]. Mitochondria were relatively recently described in neutrophils. They have relatively low density and negligible oxygen consumption rate [58]. Indeed, neutrophil pro-inflammatory action is predominantly supported via an extensive glucose utilization [59]. Activated neutrophils also synthesize NADPH, an essential cofactor for the NADPH oxidase 2 (NOX2) function specifically directed to generation of the superoxide and subsequently hydrogen peroxide (H₂O₂) (Fig. 2) [60 61]. Besides glycolysis, neutrophil bioenergetics is also partially supported by the pentose phosphate pathway (PPP) of glycolysis and glutaminolysis. Activation of Hypoxia-inducible factor-1α (HIF-1α) and the mammalian target of rapamycin (mTOR) are major metabolic signaling components that control neutrophil glycolytic phenotype [62 63]. For example, HIF-1α activates the Glut 1 and also control the expression of a number of antimicrobial factors in neutrophils, including granule proteases, antimicrobial peptides, NO, and TNF-α [64 65]. When innate immune cells are deficient in myeloid-specific HIF-1α, mice are not protected against Staphylococcus aureus sepsis, indicating that this HIF-1α pathway and glycolytic flux are integral for septic immune responses [24 66].

Figure 2

Neutrophils anti-microbial action is linked to bioenergetics

NADPH, which is required for production of ROS, is generated in PPP branch of glycolysis or from the oxidation of glutamine derived malate to pyruvate. In this manner, the biochemical pathways of glycolysis and glutaminolysis provide the microbicidal activity to activated neutrophil.

PPP, pentose phosphate pathway; ADP, adenosine diphosphate; ATP, adenosine triphosphate; ROS, reactive oxygen species; MPO myeloperoxidase; NOX2, NADPH oxidase 2; HOCI, hypochlorous acid.

Interestingly, while mitochondria have little or negligible impacts to neutrophil bioenergetics, recent studies indicate that proximal localization of mitochondria in the leading edge is crucial for optimal chemotaxis [67 68 69]. In particular, dissipation of mitochondrial membrane potential, a situation found upon exposure to bacterial product LPS, nearly completely diminished neutrophils chemotaxis [50 70]. This is relevant issue because host-generated inflammatory mediators and bacterial products are present in circulation of individuals with established sepsis. These mediators effectively prevent neutrophil chemotactic response and cause random adhesion to epithelium, and thereby cause vascular injury (Fig. 3) [71]. Previous studies have indicated that mitochondrial membrane depolarization also reduced neutrophil respiratory burst. Although this issue is directly linked to inability to kill bacteria, mechanistic insights remain to be determined [51 72]. It is important to note, ROS produced by respiratory burst, likely mitochondrial source, or simple exposure to extracellular hydrogen peroxide bolus have a significant impact on neutrophil pro-inflammatory function. Apparently, H₂O₂ is indispensable for an effective microbial eradication, but it is also preventing and/or promoting neutrophil transition from pro-inflammatory to anti-inflammatory phenotype that linked to bacterial killing (Fig. 3) [73 74]. Collectively, these new findings clearly indicate that mitochondria play a crucial role in neutrophil biology.

Figure 3

Mitochondria plays a crucial role in regulating neutrophil function.

(A) Mitochondrial function in the leading edge supports neutrophil chemotaxis. In infection site, LPS-TLR4 engagement indices mitochondrial depolarization and subsequent inhibition of neutrophil motility and promote pro-inflammatory action. Pro-bactericidal effects are activated by NADPH oxidase activation. Notably, H₂O₂ is important to bacterial killing and promote neutrophil transition from pro-inflammatory to anti-inflammatory phenotype. (B) Severe sepsis and shock is characterized by accumulation of bacterial products and DAMPs in circulation. LPS inhibits neutrophil chemotaxis and promote pro-inflammatory activation flowed by random adhesion to endothelial cells. Neutrophils extravasation and activation is implicated in tissue injury.

ATP, adenosine triphosphate; TLR, Toll-like receptor; LPS, lipopolysaccharide; NADPH, nicotinamide adenine dinucleotide phosphate; DAMPs, damage associated molecular pattern proteins.

2. Macrophages and dendritic cell

In the presence of pathogens or trauma and ischemia, macrophages rapidly switch from a resting state to a highly active pro-inflammatory state. This is associated with increased cytokines, chemokines and production of other host defense factors that enhanced phagocytosis, and later on antigen presentation. TLR4-LPS engagement is associated with acquisition of pro-inflammatory phenotype, which often called classical (M1) macrophages [75]. M1 macrophages have a high microbicidal activity and are characterized by production of pro-inflammatory cytokines and ROS. Similar to neutrophils, HIF-1α is a primary regulator of glycolytic metabolism in M1-polarized macrophages. Another important regulator of macrophage activation is carbohydrate kinase-like protein (CARKL) which is typically reduced in M1 [76]. In turn, CARKL expression promotes exit toward M2 phenotype, in which the induction of pro-inflammatory cytokines is greatly diminished [75]. This phenotype can be directly elicited by stimulation macrophages with IL-4 and IL-13. M2-polarized macrophages also participate in host defense, including neutralization of parasites, infections and stimulate tissue repair by production of anti-inflammatory cytokines and phagocytosis of dying cells [75 77]. Indeed, poor transition from M1 to M2 phenotype has detrimental impact on recovery from organ injury. For example, it has been shown that deficiency of AMP-activated protein kinase (AMPK) is directly implicated in impaired M1-to-M2 transition and disrupted clearance of apoptotic cells during the resolution phase [78 79 80 81].

M1 and M2 activation are characterized by a distinct metabolic profile that differs from resting macrophages (M0) [82]. In particular, M1 macrophages have high rates of glucose and glutamine uptake and lactic acid production with little or no flux through OxPhos [83 84]. In activated macrophages, OxPhos is inactivated following the inducible form of nitric oxide synthase (iNOS) dependent NO production; NO competes with oxygen to inhibit the terminal electron acceptor (complex IV) of mitochondrial electron transport chain [85 86]. Our recent studies indicate that preservation of major components of mitochondrial complexes is possible in a polymicrobial intra-abdominal model of sepsis [50 87]. For example, metformin is major metabolic AMPK activator that promoted mitochondrial biogenesis and thus, decreased the severity of endotoxin induced acute lung injury [50]. Notably, MAPK kinase 3 inhibition effectively preserve mitochondrial function on lung of mice subjected to endotoxin injury [88]. These finding suggest that preservation/restoration of mitochondrial function was essential for immune recovery from sepsis. Interestingly, an increment in mitochondrial ROS production is required for normal macrophage bactericidal activity [89]. In regards to the metabolic phenotype, M2 macrophages had higher rates of fatty-acid oxidation (FAO), mitochondrial biogenesis [56]. Compared to HIF-1α dependent glycolytic metabolism of M1 macrophages, equation of M2 phenotype is associated with FAO and oxidative metabolism. These are mediated by at least in part by activation of STAT6 [56] that promotes expression of genes involved in FAO and OxPhos due to mitochondrial biogenesis mediated by peroxisome-proliferator-activated receptor-γ co-activator-1β (PGC-1β) [56]. Moreover, expression of peroxisome proliferator-activated receptor (PPAR) is increased in M2 macrophages, and this supports the view that PPAR are important transcription factor that drive transition to the M2 phenotype [90].

Similarly to macrophages, dendritic cells (DC) oxidize glucose in the mitochondria through OxPhos and in response to TLR agonists. They also activate the metabolic switch for glycolytic metabolism during pro-inflammatory activation [84]. An initial increase in glycolysis occurs within minutes of DC activation. Over the course of 18 hours, activated DC sustains elevated glycolysis along with loss of OxPhos. This metabolic shift appeared to have a substantial impact in regulating DC-induced T cell responses [91].

Although above paragraph summarized major characteristics of M1 and M2 phenotypes, it is important to note that several intermediate or phenotypic deviations are likely implicated in pathophysiological conditions. For example, M1-deriven pro-inflammatory response is implicated in inflammatory organ injury, at least in a murine model of sepsis. In turn, a subsequent transition to M2 may contribute to immunosuppression. This raises a question whether these adverse effects are mediated by bioenergetic adaptations. However, a plausible explanation may be derived from two recent studies that suggest dysfunction of both oxidative phosphorylation and glycolysis occurred in immunosuppressed monocytes [55 56]. Another intriguing question is how macrophage M2 polarization accelerates resolution from organ injury, but it may also promote adverse fibrogenic remodeling. Indeed, these areas of research have recently revealed that several intermediate phenotypes of macrophages are possible [92 93]. However, current models provide unclear explanation how bioenergetics profile of immune cells support normal resolving conditions, but also can promote disease progression. This is likely linked due to local tissue environment. Further studies are needed to delineate if bioenergetic profiles of M2 macrophages is different in M2 participating in essential normal wound healing vs. M2 associated with pathological fibrosis. Similar concerns are related to participation of M2 phenotype in resolution of inflammatory conditions, though is also suggested to elicit the immunosuppressive effects.

3. T cells

A hallmark of a successful immune response is the generation of memory T cells which are antigen-specific and can be rapidly activated to respond quickly to pathogen [94]. Indeed, production of regulatory T cell (Treg) contributes to T-cell inactivation and increase severity and mortality in experimental sepsis and post sepsis complications [95 96]. T cells differ from innate cells in two important functions. First, they proliferate extensively and rapidly upon antigen specific activation. Secondly, after completion of the immune response, a subset of lymphocytes generates a long-lived, antigen-specific memory cells that mediate protection against reinfection [61 94]. As expected, the metabolic profile of these each distinct subset of lymphocytes are different depend on their bioenergetics demands. In particular, naïve T cell relies on glucose oxidation through OxPhos [97 98 99 100]. This bioenergetic profile is significantly altered when naïve T cells are stimulated through antigen or cytokine receptor-dependent mechanism. Stimulated cell undergoes rapid growth, proliferation, and acquisition of specialized effector functions. These events are supported by enhanced glycolysis and glutaminolysis [101]. For example, CD28 stimulation is linked to PI3K/Akt –dependent increases in the abundance of Glut1 on T cell membrane surface [101]. This not only enhances the uptake of glucose by activated T cells but also promotes a switch from OxPhos to glycolytic metabolism via mammalian target of rapamycin (mTOR) [94 101]. CD3, specific T cell receptor, also stimulate proliferation and strong dependence on extracellular glutamine [102]. In this study, Wang et al. observed that stimulation of resting T cells increases glycolytic flux through PPP, and glutaminolysis, while suppressing oxidation of pyruvate and fatty acids. Subsequent study revealed that although HIF-1α and Myc are rapidly induced upon T cell activation, Myc is primarily required for glycolysis, glutaminolysis, and T cell proliferation [103]. It is well-defined that following activation and proliferation, T cells differentiate into T helper (Th) 1, Th2, Th17, or Treg subsets. Activated T helper cells use glycolysis to support their effector functions [104], whereas Treg cell predominantly use OxPhos and mitochondrial FAO for development and survival [105]. Memory T cells share many of the same characteristics of naïve cell; they are long-lived, relatively inert cells with limited biosynthetic demands. Although both naïve and memory T cells are dependable on oxidative metabolism, memory T cells are metabolically unique because memory T cells are quiescent but positioned to respond rapidly. Memory T cells predominantly use FAO to generate acetyl-CoA to fuel OxPhos [106 107].

Metabolic pathways can influence not only activation of T cells, but also the development of various T helper subsets. The transitions of T cells from naïve to activation and back to memory formation are highly dependent on and regulated by cellular metabolism in response to environmental signals.

Extension of metabolic profile to diagnose outcome of sepsis

Lactate is an established marker of bioenergetic alterations in predictor of mortality in sepsis. However, recent studies indicate that patents with prior use of metformin have shown nearly 30% increase survival despite high level of lactate [108]. Notably, while lactate is among well-established predictors of sepsis, recent clinical trials have shown that decrease in lactate production had no effects on sepsis survival [109 110]. Clinical studies also suggest that lactate clearance may not be used as a surrogate marker of microcirculatory blood flow [111]. Several groups have performed broader metabolic profiling in sepsis to test whether incorporation of multiple metabolites could serve as prognostic indicators in sepsis, including identification of citrate, malate, glycerol, carnitine, sucrose, mannose, methionine, arginine and other metabolites [112 113 114]. Further metabolomic studies provide potentially valuable diagnostic markers to more accurately predict outcome in septic patients [113 115]. In particular, analysis on plasma samples for FAO, gluconeogenesis, and the Krebs cycle between revealed a defect in FAO in non-survivors [113]. Apart from the direct role of metabolites in insuring the cellular energy resources, metabolites have an underestimated their role in signaling pathways and regulation of gene expression [115]. The interaction between metabolic pathways and the epigenetic profile of the cells plays an important role in the inflammatory phenotypes of immune cells during sepsis [115]. One of the most extensively described is the deacetylase enzymes SIRT1 in sepsis. TLR4 signaling results in SIRT1 binding to NF-κB to decrease NF-κB dependent transcription of pro-inflammatory cytokine [116].

Given the mitochondrial bioenergetics dysfunction and mortality rate in sepsis [16 17], main metabolic switch AMPK, mTOR, HIF-1α and other regulator of glycolysis are among important therapeutic targets. For example, recovery of AMPK activity reduced the severity of sepsis and lung injury. AMPK also improved bacterial eradication in mouse model of peritonitis or intra-abdominal bacterial sepsis [70 117 118]. In part, AMPK activation reduced cytokine production, inhibited DAMPs release such as HMGB1 release [119]. Of note, AMPK also reduced immunosuppression through diminishment of HIF-1α and preservation of sensitivity of macrophages secondary challenge with LPS, thus reduced their immunosuppressive phenotype [50 117 120 121]. In turn, Cheng et al. have shown that HIF-1α is important for preservation immune cell function when oxygen level is limited [66]. Notably, AMPK activator AICAR used in this study has substantial off-site effects related to adverse impact on immune chemotaxis, similar to AMP, GMP and other nucleotides [66]. Moreover, recent study uncovered that specific mechanism(s) are responsible for inactivation of AMPK activity during sepsis and in immunosuppressed monocytes. Therefore, typical AMPK activators may provide optimal effects as recently observed in mouse fungal infection model [55]. Notably, targeting glycolytic pathway, including pyruvate kinase M2 (PKM2) effectively reduced the severity of sepsis [122 123]. Although this is exciting and promising area of research, it is not clear whether prior recovery of mitochondrial function is required for benefits mediated by reduced glycolytic flux toward restoration of immune homeostasis.

Conclusions

Severe sepsis and septic shock induce profound metabolic alterations and loss of bioenergetic plasticity in immune system. The pro-inflammatory phase and subsequent development of immunosuppression appear to have deficiency in mitochondrial bioenergetics of immune and parenchymal cells. Thus, pharmacological interventions that improve mitochondrial biogenesis and quality control are likely relevant for sepsis and other inflammatory conditions related to loss of bioenergetic and metabolic plasticity.

Acknowledgments

Park, D.W. was supported by grants from Korea University (K1032201, K1613721) and JW Zmijewski was supported by National Institutes of Health Grant (HL107585).

Notes

Conflict of Interest: No conflicts of interest.

References

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101:1644–1655. PMID: 1303622.

2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546–1554. PMID: 12700374.

3. Park DW, Chun BC, Kim JM, Sohn JW, Peck KR, Kim YS, Choi YH, Choi JY, Kim SI, Eom JS, Kim HY, Song JY, Song YG, Choi HJ, Kim MJ. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock: a prospective observational study in 12 university hospitals in Korea. J Korean Med Sci. 2012; 27:1308–1314. PMID: 23166410.

4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303–1310. PMID: 11445675.

5. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013; 41:1167–1174. PMID: 23442987.

6. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990; 49:186–196. PMID: 2199735.

7. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998; 9:1–11.

8. O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock. 1999; 12:411–420. PMID: 10588508.

9. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999; 27:1230–1251. PMID: 10446814.

10. Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR, Janks DL, Srivastava A, Bhayani SB, Drewry A, Swanson PE, Hotchkiss RS. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013; 187:509–517. PMID: 23348975.

11. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306:2594–2605. PMID: 22187279.

12. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014; 20:195–203. PMID: 24581450.

13. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013; 309:1154–1162. PMID: 23512062.

14. Boekstegers P, Weidenhöfer S, Pilz G, Werdan K. Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: comparison to limited infection and cardiogenic shock. Infection. 1991; 19:317–323. PMID: 1800370.

15. Sair M, Etherington PJ, Peter Winlove C, Evans TW. Tissue oxygenation and perfusion in patients with systemic sepsis. Crit Care Med. 2001; 29:1343–1349. PMID: 11445683.

16. Fink MP. Bench-to-bedside review: cytopathic hypoxia. Crit Care. 2002; 6:491–499. PMID: 12493070.

17. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348:138–150. PMID: 12519925.

18. Levy E, Slusser RJ, Ruebner BH. Hepatic changes produced by a single dose of endotoxin in the mouse. Electron microscopy. Am J Pathol. 1968; 52:477–502. PMID: 5639556.

19. Träger K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care. 2003; 9:271–278. PMID: 12883281.

20. Englert JA, Rogers AJ. Metabolism, metabolomics, and nutritional support of patients with sepsis. Clin Chest Med. 2016; 37:321–331. PMID: 27229648.

21. Delano MJ, Moldawer LL. Magic bullets and surrogate biomarkers circa 2009. Crit Care Med. 2009; 37:1796–1798. PMID: 19373047.

22. Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013; 34:129–136. PMID: 23036432.

23. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000; 343:338–344. PMID: 10922424.

24. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016; 274:330–353. PMID: 27782333.

25. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008; 8:776–787. PMID: 18802444.

26. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013; 187:1287–1293. PMID: 23590272.

27. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012; 72:1491–1501. PMID: 22695412.

28. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014; 40:463–475. PMID: 24745331.

29. Jansen TC, van Bommel J, Bakker J. Blood lactate monitoring in critically ill patients: a systematic health technology assessment. Crit Care Med. 2009; 37:2827–2839. PMID: 19707124.

30. Levraut J, Ciebiera JP, Chave S, Rabary O, Jambou P, Carles M, Grimaud D. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med. 1998; 157:1021–1026. PMID: 9563714.

31. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006; 16:R551–R560. PMID: 16860735.

32. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell. 2006; 125:1241–1252. PMID: 16814712.

33. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol. 2012; 13:780–788. PMID: 23175281.

34. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012; 26:711–723. PMID: 23168274.

35. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med. 2007; 35(Suppl):S441–S448. PMID: 17713391.

36. Larsen FJ, Schiffer TA, Weitzberg E, Lundberg JO. Regulation of mitochondrial function and energetics by reactive nitrogen oxides. Free Radic Biol Med. 2012; 53:1919–1928. PMID: 22989554.

37. Haden DW, Suliman HB, Carraway MS, Welty-Wolf KE, Ali AS, Shitara H, Yonekawa H, Piantadosi CA. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. Am J Respir Crit Care Med. 2007; 176:768–777. PMID: 17600279.

38. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014; 5:66–72. PMID: 24185508.

39. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF; Inflamm and Host Response to Injury Large Scale Collab. Res. Program. A network-based analysis of systemic inflammation in humans. Nature. 2005; 437:1032–1037. PMID: 16136080.

40. Carré JE, Orban JC, Re L, Felsmann K, Iffert W, Bauer M, Suliman HB, Piantadosi CA, Mayhew TM, Breen P, Stotz M, Singer M. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med. 2010; 182:745–751. PMID: 20538956.

41. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014; 5:4–11. PMID: 24335434.

42. Ferro TN, Goslar PW, Romanovsky AA, Petersen SR. Smoking in trauma patients: the effects on the incidence of sepsis, respiratory failure, organ failure, and mortality. J Trauma. 2010; 69:308–312. PMID: 20699738.

43. Huttunen R, Laine J, Lumio J, Vuento R, Syrjänen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis. 2007; 7:13. PMID: 17349033.

44. Boulos M, Astiz ME, Barua RS, Osman M. Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit Care Med. 2003; 31:353–358. PMID: 12576936.

45. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002; 360:219–223. PMID: 12133657.

46. Chen Y, Wang Y, Chen J, Chen X, Cao W, Chen S, Xu S, Huang H, Liu P. Roles of transcriptional corepressor RIP140 and coactivator PGC-1alpha in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes. Mol Cell Endocrinol. 2012; 362:11–18. PMID: 22503866.

47. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007; 115:2540–2548. PMID: 17502589.

48. Seth A, Steel JH, Nichol D, Pocock V, Kumaran MK, Fritah A, Mobberley M, Ryder TA, Rowlerson A, Scott J, Poutanen M, White R, Parker M. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 2007; 6:236–245. PMID: 17767910.

49. Grégoire M, Tadié JM, Uhel F, Gacouin A, Piau C, Bone N, Le Tulzo Y, Abraham E, Tarte K, Zmijewski JW. HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J Leukoc Biol. 2016; pii: jlb.5HI0316-128RR.

50. Liu Z, Bone N, Jiang S, Park DW, Tadie JM, Deshane J, Rodriguez CA, Pittet JF, Abraham E, Zmijewski JW. AMP-activated protein kinase and Glycogen Synthase Kinase 3β modulate the severity of sepsis-induced lung injury. Mol Med. 2015; [Epub ahead of print].

51. Zmijewski JW, Lorne E, Banerjee S, Abraham E. Participation of mitochondrial respiratory complex III in neutrophil activation and lung injury. Am J Physiol Lung Cell Mol Physiol. 2009; 296:L624–L634. PMID: 19168575.

52. Pelekanou A, Tsangaris I, Kotsaki A, Karagianni V, Giamarellou H, Armaganidis A, Giamarellos-Bourboulis EJ. Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit Care. 2009; 13:R172. PMID: 19883512.

53. Loftus RM, Finlay DK. Immunometabolism: cellular metabolism turns immune regulator. J Biol Chem. 2016; 291:1–10. PMID: 26534957.

54. O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med. 2016; 213:15–23. PMID: 26694970.

55. Cheng SC, Scicluna BP, Arts RJ, Gresnigt MS, Lachmandas E, Giamarellos-Bourboulis EJ, Kox M, Manjeri GR, Wagenaars JA, Cremer OL, Leentjens J, van der Meer AJ, van de Veerdonk FL, Bonten MJ, Schultz MJ, Willems PH, Pickkers P, Joosten LA, van der Poll T, Netea MG. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016; 17:406–413. PMID: 26950237.

56. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, Wagner RA, Greaves DR, Murray PJ, Chawla A. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 2006; 4:13–24. PMID: 16814729.

57. Link DC. Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res. 2005; 32:169–178. PMID: 16106067.

58. van Raam BJ, Sluiter W, de Wit E, Roos D, Verhoeven AJ, Kuijpers TW. Mitochondrial membrane potential in human neutrophils is maintained by complex III activity in the absence of supercomplex organisation. PLoS One. 2008; 3:e2013. PMID: 18431494.

59. Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest. 1982; 70:550–557. PMID: 7107894.

60. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. 2008; 112:935–945. PMID: 18684880.

61. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013; 38:633–643. PMID: 23601682.

62. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002; 277:23111–23115. PMID: 11943784.

63. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 2011; 108:4129–4134. PMID: 21325052.

64. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112:645–657. PMID: 12628185.

65. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, Hurtado-Ziola N, Nizet V, Johnson RS. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest. 2005; 115:1806–1815. PMID: 16007254.

66. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, Giamarellos-Bourboulis EJ, Martens JH, Rao NA, Aghajanirefah A, Manjeri GR, Li Y, Ifrim DC, Arts RJ, van der Veer BM, Deen PM, Logie C, O'Neill LA, Willems P, van de Veerdonk FL, van der Meer JW, Ng A, Joosten LA, Wijmenga C, Stunnenberg HG, Xavier RJ, Netea MG. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014; 345:1250684. PMID: 25258083.

67. Desai SP, Bhatia SN, Toner M, Irimia D. Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J. 2013; 104:2077–2088. PMID: 23663851.

68. Campello S, Lacalle RA, Bettella M, Manes S, Scorrano L, Viola A. Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. J Exp Med. 2006; 203:2879–2886. PMID: 17145957.

69. Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci. 2005; 118:5411–5419. PMID: 16306220.

70. Park DW, Jiang S, Tadie JM, Stigler WS, Gao Y, Deshane J, Abraham E, Zmijewski JW. Activation of AMPK enhances neutrophil chemotaxis and bacterial killing. Mol Med. 2013; 19:387–398. PMID: 24091934.

71. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013; 13:159–175. PMID: 23435331.

72. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Siegal GP, Abraham E. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med. 2008; 178:168–179. PMID: 18436790.

73. Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Abraham E. Antiinflammatory effects of hydrogen peroxide in neutrophil activation and acute lung injury. Am J Respir Crit Care Med. 2009; 179:694–704. PMID: 19151196.

74. Zmijewski JW, Banerjee S, Bae H, Friggeri A, Lazarowski ER, Abraham E. Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J Biol Chem. 2010; 285:33154–33164. PMID: 20729205.

75. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013; 493:346–355. PMID: 23325217.

76. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, Knapp B, Haas R, Schmid JA, Jandl C, Amir S, Lubec G, Park J, Esterbauer H, Bilban M, Brizuela L, Pospisilik JA, Otterbein LE, Wagner O. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 2012; 15:813–826. PMID: 22682222.

77. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011; 11:723–737. PMID: 21997792.

78. Bae HB, Zmijewski JW, Deshane JS, Tadie JM, Chaplin DD, Takashima S, Abraham E. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 2011; 25:4358–4368. PMID: 21885655.

79. Jiang S, Park DW, Stigler WS, Creighton J, Ravi S, Darley-Usmar V, Zmijewski JW. Mitochondria and AMP-activated protein kinase-dependent mechanism of efferocytosis. J Biol Chem. 2013; 288:26013–26026. PMID: 23897815.

80. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008; 181:8633–8641. PMID: 19050283.

81. Mounier R, Théret M, Arnold L, Cuvellier S, Bultot L, Göransson O, Sanz N, Ferry A, Sakamoto K, Foretz M, Viollet B, Chazaud B. AMPK α1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013; 18:251–264. PMID: 23931756.

82. Rodríguez-Prados JC, Través PG, Cuenca J, Rico D, Aragonés J, Martín-Sanz P, Cascante M, Boscá L. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010; 185:605–614. PMID: 20498354.

83. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem J. 1986; 239:121–125. PMID: 3800971.

84. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, Cross JR, Jung E, Thompson CB, Jones RG, Pearce EJ. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010; 115:4742–4749. PMID: 20351312.

85. Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, Chmielewski K, Stewart KM, Ashall J, Everts B, Pearce EJ, Driggers EM, Artyomov MN. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015; 42:419–430. PMID: 25786174.

86. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, Pearce EL, Pearce EJ. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood. 2012; 120:1422–1431. PMID: 22786879.

87. Bone NB, Liu Z, Pittet JF, Zmijewski JW. Frontline science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI. J Leukoc Biol. 2017; 101:357–365. PMID: 27733575.

88. Mannam P, Zhang X, Shan P, Zhang Y, Shinn AS, Zhang Y, Lee PJ. Endothelial MKK3 is a critical mediator of lethal murine endotoxemia and acute lung injury. J Immunol. 2013; 190:1264–1275. PMID: 23275604.

89. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, Walsh MC, Choi Y, Shadel GS, Ghosh S. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011; 472:476–480. PMID: 21525932.

90. Thomas GD, Rückerl D, Maskrey BH, Whitfield PD, Blaxter ML, Allen JE. The biology of nematode- and IL4Rα -dependent murine macrophage polarization in vivo as defined by RNA-Seq and targeted lipidomics. Blood. 2012; 120:e93–e104. PMID: 23074280.

91. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010; 327:656–661. PMID: 20133564.

92. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016; 44:450–462. PMID: 26982353.

93. Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol. 2013; 8:241–276. PMID: 23092186.

94. Ganeshan K, Chawla A. Metabolic regulation of immune responses. Annu Rev Immunol. 2014; 32:609–634. PMID: 24655299.

95. Faist E, Kupper TS, Baker CC, Chaudry IH, Dwyer J, Baue AE. Depression of cellular immunity after major injury. Its association with posttraumatic complications and its reversal with immunomodulation. Arch Surg. 1986; 121:1000–1005. PMID: 3741094.

96. Shelley O, Murphy T, Paterson H, Mannick JA, Lederer JA. Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock. 2003; 20:123–129. PMID: 12865655.

97. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013; 31:259–283. PMID: 23298210.

98. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol. 2001; 167:6869–6876. PMID: 11739504.

99. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008; 111:2101–2111. PMID: 18042802.

100. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med. 2004; 200:659–669. PMID: 15353558.

101. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002; 16:769–777. PMID: 12121659.

102. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, Turay AM, Frauwirth KA. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010; 185:1037–1044. PMID: 20554958.

103. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J, Green DR. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35:871–882. PMID: 22195744.

104. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011; 208:1367–1376. PMID: 21708926.

105. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011; 186:3299–3303. PMID: 21317389.

106. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009; 460:103–107. PMID: 19494812.

107. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, Chang CH, Smith AM, Ai T, Faubert B, Jones RG, Pearce EJ, Pearce EL. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci USA. 2013; 110:14336–14341. PMID: 23940348.

108. Park J, Hwang SY, Jo IJ, Jeon K, Suh GY, Lee TR, Yoon H, Cha WC, Sim MS, Carriere KC, Yeon S, Shin TG. Impact of metformin use on lactate kinetics in patients with evere sepsis and septic shock. Shock. 2016; [Epub ahead of print].

109. Lokhandwala S, Andersen LW, Nair S, Patel P, Cocchi MN, Donnino MW. Absolute lactate value vs relative reduction as a predictor of mortality in severe sepsis and septic shock. J Crit Care. 2017; 37:179–184. PMID: 27771598.

110. Varis E, Pettilä V, Poukkanen M, Jakob SM, Karlsson S, Perner A, Takala J, Wilkman E; FINNAKI study group. Evolution of blood lactate and 90-day mortality in septic shock. A post hoc analysis of the Finnaki study. Shock. 2016; [Epub ahead of print].

111. Puskarich MA, Shapiro NI, Massey MJ, Kline JA, Jones AE. Lactate clearance in septic shock is not a surrogate for improved microcirculatory flow. Acad Emerg Med. 2016; 23:690–693. PMID: 26825368.

112. Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med. 2013; 187:967–976. PMID: 23471468.

113. Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, Chen B, Carin L, Suarez A, Mohney RP, Freeman DH, Wang M, You J, Wulff J, Thompson JW, Moseley MA, Reisinger S, Edmonds BT, Grinnell B, Nelson DR, Dinwiddie DL, Miller NA, Saunders CJ, Soden SS, Rogers AJ, Gazourian L, Fredenburgh LE, Massaro AF, Baron RM, Choi AM, Corey GR, Ginsburg GS, Cairns CB, Otero RM, Fowler VG Jr, Rivers EP, Woods CW, Kingsmore SF. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013; 5:195ra95.

114. Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, Fredenburgh LE, Hunninghake GM, Raby BA, Matthay MA, Otero RM, Fowler VG, Rivers EP, Woods CW, Kingsmore S, Langley RJ, Choi AM. Metabolomic derangements are associated with mortality in critically ill adult patients. PLoS One. 2014; 9:e87538. PMID: 24498130.

115. Arts RJ, Gresnigt MS, Joosten LA, Netea MG. Cellular metabolism of myeloid cells in sepsis. J Leukoc Biol. 2017; 101:151–164. PMID: 27272310.

116. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23:2369–2380. PMID: 15152190.

117. Zhao X, Zmijewski JW, Lorne E, Liu G, Park YJ, Tsuruta Y, Abraham E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 295:L497–L504. PMID: 18586954.

118. Park DW, Jiang S, Liu Y, Siegal GP, Inoki K, Abraham E, Zmijewski JW. GSK3 β-dependent inhibition of AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014; 307:L735–L745. PMID: 25239914.

119. Tadie JM, Bae HB, Deshane JS, Bell CP, Lazarowski ER, Chaplin DD, Thannickal VJ, Abraham E, Zmijewski JW. Toll-like receptor 4 engagement inhibits adenosine 5′-monophosphate-activated protein kinase activation through a high mobility group box 1 protein-dependent mechanism. Mol Med. 2012; 18:659–668. PMID: 22396017.

120. Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Kim KR, Cheon HG. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem. 2014; 289:23246–23255. PMID: 24973221.

121. Escobar DA, Botero-Quintero AM, Kautza BC, Luciano J, Loughran P, Darwiche S, Rosengart MR, Zuckerbraun BS, Gomez H. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res. 2015; 194:262–272. PMID: 25456115.

122. Yang L, Xie M, Yang M, Yu Y, Zhu S, Hou W, Kang R, Lotze MT, Billiar TR, Wang H, Cao L, Tang D. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun. 2014; 5:4436. PMID: 25019241.

123. Xie M, Yu Y, Kang R, Zhu S, Yang L, Zeng L, Sun X, Yang M, Billiar TR, Wang H, Cao L, Jiang J, Tang D. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat Commun. 2016; 7:13280. PMID: 27779186.

TOOLS

Similar articles